CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT
|
|
- May Harrell
- 5 years ago
- Views:
Transcription
1 Daniel Heng, MD, MPH, Chair GU Tumour Group, Tom Baker Cancer Centre Clinical Professor, University of Calgary CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT
2 Disclosures Consultancies and/or research funding from BMS Eisai Ipsen Novartis Pfizer
3 Prognostic Factors Outline First Line Therapy Advances Cytoreductive Nephrectomy Second line therapy Evolving Algorithm The Future
4 mrcc treatment Treating Metastatic RCC Start drug therapy More common Cytoreductive nephrectomy then targeted therapy Active surveillance (small, slow growth) Metastasectomy (solitary, resectable, disease-free interval) Better prognosis 4
5 International mrcc Database Consortium PROGNOSTIC FACTORS
6 International mrcc Database Consortium Currently includes 9,500 patients from 38 international institutions Poland Italy 6
7 Risk Stratification International mrcc Database Consortium (IMDC) Prognostic Factors Clinical Low Karnofsky performance (<80%) Time from diagnosis to treatment <1 year Laboratory Low hemoglobin (< LLN) High corrected serum calcium (> ULN) High neutrophils (> ULN) High levels of platelets (> ULN) Categorized into 3 risk groups with decreasing associated survival time Favorable (0 factors) Intermediate (1 2 factors) Poor (3+ factors) Heng DY, et al. J Clin Oncol. 2009;27:
8 IMDC Prognostic Factors Favorable 43 months 43 mo Intermediate 23 months 23 mo Poor 8 mo Heng DY, et al. Lancet Oncol. 2013;14:
9 IMDC in Second-Line Targeted Therapy Poor 5.4 mo Int 16.6 mo Favorable 35.3 mo Ko JJ, et al. GU Cancers Symposium Abstract
10 IMDC in Third-Line Targeted Therapy Wells JC, et al. Eur Urol. 2016;71:
11 IMDC in Non-clear Cell RCC Kroeger N, et al. Cancer. 2013;119: IMDC in Papillary RCC TKI First Line Wells JC, et al. Cancer Med. 2017;6: IMDC in Nivolumab Second Line Yip S, et al. ASCO 2018 Abstract
12 How Do We Use Prognostic Factors? Patient counseling Clinical trial stratification and adjustment methods in retrospective studies Patient treatment Temsirolimus can be used in poor-risk individuals Can help determine prognosis for deciding whether cytoreductive nephrectomy can be helpful Can help choose first-line therapy 12
13 FIRST-LINE THERAPY
14 PFS probability IMDC: Comparative Effectiveness of First-Line Pazopanib and Sunitinib OS probability Progression-free survival Overall survival Median PFS, months (95% CI) Pazopanib (n = 914): 8.3 ( ) Sunitinib (n = 6,493): 8.4 ( ) P = Median OS, months (95% CI) Pazopanib (n = 915): 22.6 ( ) Sunitinib (n = 6,490): 22.3 ( ) 0.8 P = Time, months Time, months ORR between sunitinib and pazopanib (1687/5561 [30%] vs 196/707 [28%], respectively; Fisher s exact test = 0.16) Ruiz-Morales JM, et al. Eur J Cancer. 2016;65:
15 CheckMate 214: Study Design Patients Treatment Treatment-naive advanced or metastatic clear cell RCC Measurable disease KPS 70% Tumor tissue available for PD-L1 testing Randomize 1:1 Stratified by IMDC prognostic score (0 vs 1 2 vs 3 6) Region (US vs Canada/Europe vs rest of world) Arm A 3 mg/kg nivolumab IV + 1 mg/kg ipilimumab IV Q3W for 4 doses, then 3 mg/kg nivolumab IV Q2W Arm B 50 mg sunitinib orally once daily for 4 weeks (6-week cycles) Treatment until progression or unacceptable toxicity IMDC, International Metastatic RCC Database Consortium; KPS, Karnofsky performance status; Q2W, every 2 weeks; Q3W, every 3 weeks. Escudier B, et al. Ann Oncol. 2017;28(suppl 5):v605-v
16 Co-primary endpoint Overall survival (probability) OS: IMDC Intermediate/Poor Risk No. at risk NIVO + IPI SUN Months Median OS, months (95% CI) NIVO + IPI SUN NR (28.2 NE) 26.0 (22.1 NE) Hazard ratio (99.8% CI) = 0.63 ( ) P < Escudier B, et al. Ann Oncol. 2017;28(suppl 5):v605-v
17 Exploratory endpoint ORR and PFS: IMDC Favorable Risk Outcome Confirmed ORR, % (95% CI) PFS, median (95% CI), months NIVO + IPI N = 125 N = 249* SUN N = (21 38) 52 (43 61) P = ( ) 25.1 (20.9 NE) HR (99.1% CI) = 2.18 ( ) P <.0001 *Eleven percent of patients in both arms had tumor PD-L1 expression 1%. IRRC assessed by RECIST v1.1. IRRC assessed. Escudier B, et al. Ann Oncol. 2017;28(suppl 5):v605-v
18 First-Line Therapy: Practice-Changing Ipi/Nivo for first line in IMDC intermediate/poor-risk patients These patients may have higher inflammatory and tumor burden to give IO agents something to potentiate PD-L1 is not predictive for OS don t order it But it is for PFS PD-L1 enriches patient population for responders but does not determine which patient should receive frontline IO; poor negative predictive value Important to remember RCC is still addicted to angiogenesis 18
19 Phase III First-Line IO Combinations CheckMate 214* Ipilimumab/Nivolumab VS Sunitinib CheckMate 9ER Cabozantinib/Nivo VS Sunitinib JAVELIN Renal 101 Axitinib/Avelumab VS Sunitinib *Results available. IMmotion151* Bevacizumab/ Atezolizumab VS Sunitinib EISAI 307 Lenvatinib/Everolimus VS Lenvatinib/Pembro VS Sunitinib KEYNOTE-426 Axitinib/Pembrolizumab VS Sunitinib 19
20 To Cut or Not to Cut? CYTOREDUCTIVE NEPHRECTOMY
21 Value of Cytoreductive Nephrectomy OS benefit of nephrectomy compared with no nephrectomy in mrcc patients treated with targeted therapies*, retrospective analysis 3,245 mrcc patients 2,569 (79%) patients with nephrectomy Excluded: 1,587 (49%) patients with nephrectomy before metastases 676/1,658 (41%) No cytoreductive nephrectomy 982/1,658 (59%) Cytoreductive nephrectomy* *Sunitinib (67%); sorafenib (20%); bevacizumab (4%); temsirolimus (3.6%); pazopanib (2.8%); other (2.6%). Sunitinib (79%); sorafenib (8.6%); bevacizumab (1.5%); temsirolimus (6.4%); pazopanib (2.8%); other (1.7%). Heng DY, et al. Eur Urol. 2014;66:
22 OS probability Cytoreductive Nephrectomy Has a Favorable Effect on OS 1.00 Median OS + CN (n = 982) 20.6 months CN (n = 676) 9.5 months 0.8 HR* = 0.60 (95% CI: ) P < Time, months *Adjusted for IMDC criteria. HR, hazard ratio. Heng DY, et al. Eur Urol. 2014;66:
23 IMDC Prognostic Factors Predict Benefit From Cytoreductive Nephrectomy Number of IMDC factors No nephrectomy OS, months (n) Nephrectomy OS, months (n) P value 0 92% of patients with nephrectomy; insufficient number to compare (72) 30.4 (178) (143) 20.2 (253) < (113) 15.9 (106) < (103) 6.0 (67) (36) 2.8 (14) % of patients without nephrectomy; insufficient number to compare Heng DY, et al. Eur Urol. 2014;66:
24 CARMENA: Cytoreductive Nephrectomy Mejean A, et al. ASCO Abstract LBA3. 24
25 Patient Characteristics Mejean A, et al. ASCO Abstract LBA3. 25
26 Overall Survival by Patient Population Mejean A, et al. ASCO Abstract LBA3. 26
27 Cytoreductive Nephrectomy With CARMENA, cytoreductive nephrectomy threshold is higher: caveats due to trial issues More intermediate/poor-risk patients should receive systemic therapy first; also consider deferred nephrectomy per SURTIME It is still about patient selection Poor-risk patients do not benefit from CN and should be started on targeted therapy I would still do CN in Favorable risk: Large kidney mass if removed can do surveillance Int risk: Large kidney mass with a few small pulmonary nodules Bleeding or painful kidney mass in low-bulk metastatic disease Heng DY, et al. Eur Urol. 2014;66:
28 SECOND LINE AND BEYOND
29
30 Overall survival Presented by Robert Motzer at Genitourinary Cancers Symposium 2016.
31 Immune-mediated Adverse Reactions Result from increased I MMUNE-MEDI or excessive immune ATED activity ADVERSE REACTI ONS Can be severe or Follow life-threatening, color code affecting to appropriate various management organs guide section. GASTROINTESTINAL GOTOPAGE6 Signs and symptoms such as Diarrhea Abdominal pain Blood or mucus in stool Bowel perforation Peritoneal signs Ileus LIVER GOTOPAGE8 Signs such as Abnormal liver function tests (eg, AST, ALT) or total bilirubin SKIN GOTOPAGE10 Symptoms such as Pruritus Rash NEUROLOGIC GOTOPAGE12 Symptoms such as Unilateral or bilateral weakness Sensory alterations Paresthesia ENDOCRINE GOTOPAGE14 Signs and symptoms such as Fatigue Headache Mental status changes Abdominal pain Unusual bowel habits Hypotension Abnormal thyroid function tests and/or serum chemistries OTHER ADVERSE REACTIONS, including ocular manifestations GOTOPAGE16 ference ID: Approved Please see each organ system section for related guidance. See checklist on the next page. 3
32 Cabozantinib Phase III Study (METEOR): Design Phase III randomised, multicentre, open-label study to evaluate the efficacy and safety of cabozantinib vs everolimus in patients with RCC who had progressed on prior VEGFR therapy Patients 18 years of age Advanced/Metastatic clear cell RCC Measurable disease Received 1 prior VEGFR therapy and progressed 6 months after most recent dose Karnofsky PS 70 Adequate organ and bone marrow function Stratification factors Number of previous VEGFR therapies MSKCC criteria Cabozantinib 60 mg oral OD Randomisation 1:1 No crossover allowed Tumour assessment every 8 weeks (RECIST v1.1) Treatment until loss of clinical benefit or intolerable toxicity Everolimus 10 mg oral OD Endpoints Primary PFS* (independent review) Secondary OS ORR Safety MSKCC, Memorial Sloan Kettering Cancer Center; OD, daily; PS, performance status. *PFS defined as the interval between the dates of randomisation and first documentation of disease progression or death from any cause. 1. Choueiri TK, et al. N Engl J Med. 2015;373:
33 Roles of MET and AXL in RCC MET and AXL in RCC Receptor Activation and tumourigenic activities MET 2 Loss of VHL expression/vhl mutation and hypoxia lead to upregulation of MET in ccrcc Activation of MET through gene mutations identified in hereditary/sporadic papillary RCC Dysregulation of MET implicated in tumour development, invasion, and angiogenesis AXL expression directly activated by HIF-1 and HIF-2 AXL 3 In metastatic ccrcc, inactivation of AXL reverses invasive and metastatic phenotype AXL expression in primary ccrcc tumours correlates with aggressive tumour behaviour and increased risk of patient mortality Increased expression of MET and AXL in RCC is associated with poor prognosis and resistance to VEGFR inhibitors 1,3 ccrcc, clear-cell RCC; MET, hepatocyte growth factor receptor 1. Choueiri TK, et al. N Engl J Med 2015;373: ; 2. Gibney GT, et al. Ann Oncol; 2013;24:343 9; 3. Rankin EB, et al. PNAS 2014;111:
34 METEOR Study: OS Second Interim Analysis (ITT population) Overall survival, % No. of patients Median overall survival (95% CI), mo No. of deaths Cabozantinib (18.7 NE) 140 Everolimus ( ) HR = 0.66 (95% Cl: ; P =.0003) No. at Risk Cabozantinib Everolimus 0 Cabozantinib Everolimus Months Data cutoff: 31 Dec Choueiri TK, et al. Lancet Oncol. 2016;17:
35 Cabozantinib Phase 1 Study: Activity Against Bone Metastases Clinical activity against metastatic lesions in bone was observed in some patients This scan shows partial bone resolution in a symptomatic RCC patient with predominantly osteolytic bone metastases who was previously treated with sorafenib, everolimus, and sunitinib This patient reduced the number of narcotics (3 opioid medications to 2) and their frequency (6-7 doses of narcotics per day to 2-3 doses per day or less), continuing on reduced narcotics until Week 25 when pain began to increase in intensity 1. Choueiri TK, et al. Ann Oncol 2014;25: (supplementary data)
36 IMDC Real World Evidence: 2 nd line Cabozantinib vs Nivolumab Cabozantinib N= 53 Nivolumab N=225 IMDC Risk Category (p=0.8766) Favorable Risk 6/39 (15%) 21/157 (13%) Intermediate Risk 27/39 (69%) 107/157 (68%) Poor Risk 6/39 (15%) 29/157 (19%) Best Response: CR 1/40 (3%) 2/140 (1%) PR 7/40 (18%) 28/140 (20%) SD 23/40 (58%) 48/140 (34%) PD 9/40 (23%) 62/140 (44%) ORR 8/40 (20%) 30/140 (21%) Stukalin et al GU ASCO 2018
37 IMDC Real World Evidence: 2 nd line Cabozantinib vs Nivolumab Stukalin et al GU ASCO 2018
38 IMDC Real World Evidence: 2 nd line Cabozantinib vs Nivolumab Stukalin et al GU ASCO 2018
39 Case Presentation 67M IMDC favorable risk metastatic RCC to pancreas (largest 2.7 cm) and liver (largest 4 cm) Original nephrectomy clear cell RCC Oct 1994 Biopsy proven liver mets: clear cell RCC First-line sunitinib Aug Nov 2013 Dose reduced to 37.5mg 4/2 Best response SD but eventual PD (15 months) Case Provided by D Heng
40 Case Presentation Second-line cabozantinib Jan 2014-Feb 2017 On METEOR trial, excellent disease response Central necrosis followed by tumor regression Breaks and dose reduction to 40mg for diarrhea Liver lesions 6.4 cm max and pancreatic lesions 4.4 cm max. Had PR, but eventual PD THREE YEARS later Case Provided by D Heng
41 Patient on Cabozantinib Case Provided by D Heng
42 Case Presentation Third-line Axitinib Mar 2017 to Apr 2017 Did not tolerate due to diarrhea, fatigue, volume depletion even at dose reduction of 2mg bid Continued disease progression (PD) Fourth-line Nivolumab May 2017 to November 2017 Stable disease Eventual referral to palliative care Case Provided by D Heng
43 EVOLVING TREATMENT ALGORITHM
44 How do we choose therapy? IMDC risk group IV vs oral therapy Patient preference Side effect profiles Contraindications
45 Metastatic Renal Cell Carcinoma: Evolving Treatment Algorithm Future? Present Past Sunitinib/ Pazopanib Everolimus/ Axitinib Therapy not previously used FAV risk (~25%) Pazopanib/ Sunitinib Cabozantinib/ Nivolumab Axitinib/ Lenvatinib + Eve Therapy not previously used INT/POOR risk (~75%) Ipilimumab / Nivolumab Therapy not previously used (see above) Therapy not previously used Composite Predictive Biomarker Immune Therapy VEGF Ipilimumab Nivolumab Cabozantinib Sun/Pazo etc mtor Everolimus
46 Metastatic Renal Cell Carcinoma ADVANCING PRECISION MEDICINE
47 47
48
49 49
50 PBRM1 LOF Mutations Enrich for Benefit From Anti PD-1 Therapy Whole exome sequencing of 35 clear cell RCCs treated with anti PD-1 Validated in additional 63 patients Miao D, et al. Science. 2018;359:
51 The Future PD-L1 <1% HR = 1.00 ( ) PD-L1 1% HR = 0.48 ( ) PBRM1 LOF mutations for PD-1 inhibitors Miao D, et al. Science. 2018;359: CheckMate 214 Motzer RJ, et al. N Engl J Med. 2018;378: TSC1/TSC2/mTOR for mtor inhibitors Kwiatkowski DJ, et al. Clin Cancer Res. 2016;22:
52 Conclusions Small steps toward precision IMDC criteria can be used PDL1 testing not helpful yet mrcc is still addicted to angiogenesis: importance of VEGF inh Patient selection is key for cytoreductive nephrectomy Biomarkers remain elusive, but stay tuned 52
53 THANK
Metastatic renal cancer (mrcc): Evidence-based treatment
Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationI Kid(ney) You Not: Updates on Renal Cell Carcinoma
Disclosures I Kid(ney) You Not: Updates on Renal Cell Carcinoma Nothing to disclose Renee McAlister, PharmD, BCOP Clinical Pharmacist, GU/Melanoma Vanderbilt Ingram Cancer Center September 29, 2018 Objectives
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationPrognostic Factors for mrcc: Relevance in Clinical Practice
Prognostic Factors for mrcc: Relevance in Clinical Practice Daniel Heng MD MPH FRCPC Chair, GU Tumor Group Tom Baker Cancer Center University of Calgary Prognostic Factors Patient Factors Performance Status
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationNEXT GENERATION DRUGS IN KIDNEY CANCER. Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden
NEXT GENERATION DRUGS IN KIDNEY CANCER Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden KIDNEY CANCER SUBTYPES Papillary Type 1 and 2 Medullary Collecting duct Chromophobe Translocation Clear cell
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationIntegrating novel therapy in advanced renal cell carcinoma
Integrating novel therapy in advanced renal cell carcinoma Tian Zhang, MD Assistant Professor of Medicine GU Oncology Duke Cancer Institute March 11, 2017 Disclosures Research Funding Janssen Pfizer Consultant
More informationInnovaciones en el tratamiento del ca ncer renal. Enrique Grande
Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationThe Therapeutic Landscape in Advanced Renal Cell Carcinoma
The Therapeutic Landscape in Advanced Renal Cell Carcinoma Cora Sternberg, MD, FACP Chairman, Department of Medical Oncology San Camillo-Forlanini Hospital Rome, Italy What best describes the change in
More informationManagement of High Risk Renal Cell Carcinoma
Management of High Risk Renal Cell Carcinoma Peter E. Clark, MD Professor and Chair, Department of Urology Carolinas HealthCare System Chair, Urologic Oncology Levine Cancer Institute October 14, 2017
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationCytoreductive Nephrectomy
Cytoreductive Nephrectomy Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology Outline The Historics of CN The current status of CN The importance of patient selection Cytoreductive
More informationSecond - Line Debate: Axitinib
Second - Line Debate: Axitinib Alain Ravaud, MD PhD Bordeaux, France DISCLOSURES Member of Global, European and/or French advisory board in RCC and/or GU tumors for Pfizer, Novartis, GSK, Roche, BMS, Merck.
More informationRenal Cell Carcinoma: Navigating a Maze of Choices
Renal Cell Carcinoma: Navigating a Maze of Choices Sumanta Kumar Pal, M.D. Associate Professor Department of Medical Oncology & Experimental Therapeutics Co-Director, Kidney Cancer Program City of Hope
More informationCharacterization of Patients with Poor-
Characterization of Patients with Poor- Risk Metastatic Renal Cell Carcinoma Hamieh L 1 *, McKay RR 1 *, Lin X 2, Simantov R 2, Choueiri TK 1 *Equal contributions 1 Dana-Farber Cancer Institute, Boston,
More informationRenal Cell Cancer: Present and Future. Bernard Escudier, Gustave Roussy
Renal Cell Cancer: Present and Future Bernard Escudier, Gustave Roussy [HKIOF May 2017] Sponsored by Bristol- Myers Squibb OPDIVO Hong Kong prescribing information is available upon request Disclosures
More informationImmunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationNew strategies and future of target therapy in advanced kidney cancer
New strategies and future of target therapy in advanced kidney cancer VHL Gene Inactivation VHL Complex Disrupted VHL Protein HIF1-a, HIF2-a Accumulation VEGF PDGF TGF-α, CXCR4 Angiogenesis Endothelial
More informationEmerging Biomarkers of VEGF and mtor Inhibitors in 2015
Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Laurence Albiges Institut Gustave Roussy, France Fourteenth International Kidney Cancer Symposium Miami, Florida, USA November 6-7, 2015 www.kidneycancersymposium.com
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationTreatment Algorithm and Therapy Management in mrcc. Manuela Schmidinger Medical University of Vienna Austria
Treatment Algorithm and Therapy Management in mrcc Manuela Schmidinger Medical University of Vienna Austria A Paradigm Shift in the Treatment of mrcc 1. Sunitinib 2. Sorafenib 3. Bevacizumab+IFN-alpha
More informationAlternativas de Futuro en Cáncer Renal Enrique Grande
Alternativas de Futuro en Cáncer Renal Enrique Grande Hospital Ramón y Cajal de Madrid The ncreasingly Challenging Field of mrcc Sorafenib (US 2005, EU 2006) 3,4 Sunitinib (US & EU 2006) 3,4 Early 1940s:
More informationAdvances in the Treatment of Renal Cell Carcinoma
Advances in the Treatment of Renal Cell Carcinoma Developed in collaboration Learning Objectives Upon completion, participants should be able to: Identify patients with metastatic renal cell carcinoma
More informationpan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma
pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma Pfizer Canada Inc. June 29, 2017 3 Stakeholder Feedback on a pcodr
More informationA Review in the Treatment Options for Renal Cell Cancer
A Review in the Treatment Options for Renal Cell Cancer Ali McBride, PharmD, MS BCPS, BCOP Clinical Coordinator Hematology/Oncology Department of Pharmacy The University of Arizona Cancer Center RENAL
More informationCarcinoma renale metastatico: cambia la pratica clinica? Camillo Porta Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia
Carcinoma renale metastatico: cambia la pratica clinica? Camillo Porta Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia New target, new agent (James Brugarolas) Atezolizumab + Bevacizumab and PD-L1
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationWhy was HOPE 205 a Positive After Years of Negative Studies?
Why was HOPE 205 a Positive After Years of Negative Studies? Prof. Dr. med. Viktor Grünwald Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation Why do we pursue combinations?
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
ipilimumab aligned with patient values. Although few patients had direct experience using this combination agent, patients indicated that side effects associated with nivolumab plus ipilimumab were few
More informationA randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care
A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care Martin H. Voss 1, Thomas Hutson 2, Arif Hussain 3, Ulka
More informationCheckpointinhibitoren in der Uro-Onkologie. Carsten Grüllich
Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer
More informationLinee guida terapeutiche oncologiche. Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona
Linee guida terapeutiche oncologiche Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona 1 YOUNG SPECIALIST RENAL CARE Verona, 07-08 Marzo 2014 Clinical
More informationWinship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients
Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Bradley Carthon, MD, PhD Assistant Professor, Genitourinary Medical Oncology Winship
More informationNivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial
Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,
More informationESMO Madrid, Spain Associate Professor Brian Costello Division of Medical Oncology, Genitourinary Tumour Group, Mayo Clinic, USA
ESMO 2017 - Madrid, Spain Associate Professor Brian Costello Division of Medical Oncology, Genitourinary Tumour Group, Mayo Clinic, USA HIGHLIGHTS ON RENAL CELL CARCINOMA CHECKMATE 214: EFFICACY AND SAFETY
More informationClinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.
Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationImmunotherapy for Genitourinary Cancers
Immunotherapy for Genitourinary Cancers Susan F. Slovin, MD, PhD Genitourinary Oncology Service Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan Kettering Cancer Center New York, New
More informationRenal Cell Carcinoma: Status of Medical and Surgical Therapy. Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation
Renal Cell Carcinoma: Status of Medical and Surgical Therapy Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation Metastatic Renal Cell Carcinoma: Evolution of Current Therapeutic Approaches
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationTargeted Therapy in Advanced Renal Cell Carcinoma
Targeted Therapy in Advanced Renal Cell Carcinoma Brian I. Rini, M.D. Department of Solid Tumor Oncology Glickman Urologic and Kidney Institute Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio
More information17th ESO-ESMO Masterclass Clinical Oncology
Metastatic Renal Cell Cancer: Evidence Based Treatment Manuela Schmidinger Medical University of Vienna, Austria Disclosures Honoraria for lectures or advisory boards from: Pfizer, Roche, BMS, Novartis,
More informationASCO 2011 Genitourinary Cancer
ASCO 2011 Genitourinary Cancer Expanding Options for Chronic Diseases? Walter Stadler, MD, FACP University of Chicago Disclosures (All Non-University &/or Financial Dealings with Potential, Real, or Perceived
More informationSurgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?
Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer
More informationComplete Remission is a Reachable Goal in mrcc L. Albiges Institut Gustave Roussy
Complete Remission is a Reachable Goal in mrcc L. Albiges Institut Gustave Roussy Is complete remission an achievable goal in mrcc? Lessons from observation Lessons from immunotherapy Current status in
More informationBrain mets under I.O.
Brain mets under I.O. Bernard Escudier Gustave Roussy, Villejuif, France Disclosure Honorarium received from BMS, Novartis, Pfizer, Bayer, Roche, Exelixis, Ipsen, Eisai, Calithera Travel Grant from BMS,
More informationProspettive future nel trattamento medico del mrcc. Francesco Massari Oncologia Medica Policlinico S Orsola-Malpighi Bologna
Prospettive future nel trattamento medico del mrcc Francesco Massari Oncologia Medica Policlinico S Orsola-Malpighi Bologna 3 rd YOUNG SPECIALIST RENAL CARE Firenze, 09 Aprile 2016 Renal cell carcinoma
More informationPrognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will Be Used?
european urology supplements 8 (2009) 478 482 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationMetastatic Renal Cancer Medical Treatment
Metastatic Renal Cancer Medical Treatment Bohuslav Melichar, M.D., Ph.D. Professor and Head Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc, Czech Republic Peculiarities
More informationOvercoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016
Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016 Overcoming toxicity A new context for evaluating toxicity
More informationHow does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy
How does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Targeting VHL/HIF in Clear Cell RCC VHL Bevacizumab (Antibody)
More informationA Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients
A Phase II Study of With or Without Bevacizumab vs in Untreated Metastatic Renal Cell Carcinoma Patients David McDermott, 1 Michael Atkins, 2 Robert Motzer, 3 Brian Rini, 4 Bernard Escudier, 5 Lawrence
More informationSequential Therapy in Renal Cell Carcinoma*
Sequential Therapy in Renal Cell Carcinoma* Bernard Escudier, MD, Marine Gross Goupil, MD, Christophe Massard, MD, and Karim Fizazi, MD, PhD Because of the recent approval of several drugs for the treatment
More informationKidney Cancer Session
New Frontiers in Urologic Oncology September 12 th, 2015 Kidney Cancer Session Moderator: Philippe E. Spiess, M.D. Invited Faculty Members: Wade J. Sexton, MD Jeremiah J. Morrissey, PhD Agenda for Session
More informationMEDICAL MANAGEMENT OF METASTATIC GEP-NET
MEDICAL MANAGEMENT OF METASTATIC GEP-NET Jeremy Kortmansky, MD Associate Professor of Clinical Medicine Yale Cancer Center DISCLOSURES: NONE Introduction Gastrointestinal and pancreatic neuroendocrine
More informationMedical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce
Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce Medical treatment of metastatic RCC in the elderly ( 65y): Members of the SIOG Taskforce
More informationA Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients
A Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients Viktor Grünwald, 1 David McDermott, 2 Michael Atkins, 3 Robert Motzer, 4
More informationTreatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents
Conflict of Interest Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents None Patrick Medina, PharmD, BCOP Associate Professor University of Oklahoma OKC, OK Learning Objectives Epidemiology
More informationPieter de Mulder Lecture
Pieter de Mulder Lecture From cytokines to targeted therapies to immunotherapy: 30 years of progress in advanced RCC Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome,
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016
pan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report
More informationÍndice. Melanoma Cáncer de Pulmón Otros tumores
Índice Melanoma Cáncer de Pulmón Otros tumores Carcinoma de Vejiga Carcinoma de Células Renales Carcinoma de Cabeza y Cuello Carcinomas del tubo digestivo Cáncer de Mama MELANOMA CIRUGÍA CIRUGÍA + INFa
More informationRevisione Oral Abstracts
Revisione Oral Abstracts Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi UPDATES and NEWS from the Genitourinary Cancers Symposium - Milano,
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationMultidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 20 April, Antalya, Turkey RCC European Union 60.000 new diagnoses/year 26.000 Cancer related deaths
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationCANCER UROLOGY VOL. 12. P. S. Borisov 1, M. I. Shkol nik 2, R. V. Orlova 3, P. A. Karlov 1 DOI: /
CANCER UROLOGY 3 6 VOL. The use of targeted therapies and selection of the optimal treatment sequence in heterogeneous population of patients with metastatic kidney cancer. Results of retrospective study
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationTratamiento adyuvante y neoadyuvante del cáncer renal en Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet.
Tratamiento adyuvante y neoadyuvante del cáncer renal en 2017 Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet. Barcelona Pronóstico del CR mediante un sistema integrado en 468 pts
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationReference No: Author(s) Approval date: June Committee. Operational Date: July Review:
Reference No: Title: Author(s) Systemic anti-cancer therapy (SACT) guidelines for renal cell cancer Dr Alison Clayton Consultant Medical Oncologist & Dr Jane Hurwitz Consultant Medical Oncologist, Cancer
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationFifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationWhat can we expect from running phase III trials: will all of them alter the current treatment algorithm?
What can we expect from running phase III trials: will all of them alter the current treatment algorithm? 8 th European International Kidney Cancer Symposium Budapest, May 2013 Martin Gore PhD FRCP Royal
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationThe Use of Inhibitors of Angiogenesis in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Guideline Recommendations
Evidence-Based Series #3-8-4: Section 1 The Use of Inhibitors of Angiogenesis in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Guideline Recommendations S. Hotte, T. Waldron,
More informationMedia Release. Basel, 6 th February 2018
Media Release Basel, 6 th February 2018 Phase III IMmotion151 study showed Roche's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain
More information